Study · Randomized controlled trial · n = 127 · 2022

14 results

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT

JAMA1 Jan 2022Cited by 749 (Europe PMC)

PMID35015037PMCIDPMC8753508DOI10.1001/jama.2021.23619PepBankPUB-35015037

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, liraglutide 3.0 mg daily reduced body weight by 6.4% at week 68, less than semaglutide 2.4 mg weekly (15.8%).
In plain wordsIn adults with overweight or obesity, liraglutide caused 6.4% weight loss over 68 weeks, less than the 15.8% with semaglutide.
Peptide
Liraglutide
Outcome
DecreasePercentage change in body weight at week 68 versus semaglutide
Study
n = 127
Comparator
Semaglutide 2.4 mg
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg once daily · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Weight change
−6.4%
liraglutide 3.0 mg
Source sentences
Summary
The mean weight change from baseline was -15.8% with semaglutide vs -6.4% with liraglutide (difference, -9.4 percentage points [95% CI, -12.0 to -6.8]; P < .001); weight change with pooled placebo was -1.9%.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503708
02HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, semaglutide 2.4 mg reduced body weight by 15.8% versus 6.4% with liraglutide 3.0 mg at week 68.
In plain wordsIn adults with overweight or obesity, semaglutide led to more weight loss than liraglutide after 68 weeks.
Peptide
Semaglutide
Outcome
DecreasePercentage change in body weight, semaglutide vs liraglutide
Study
n: not reported in source
Comparator
Liraglutide 3.0 mg once daily
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Mean weight change
−15.8%
semaglutide
Mean weight change
−6.4%
liraglutide
Difference
−9.4 percentage points
semaglutide vs liraglutide
Source sentences
Summary
The mean weight change from baseline was -15.8% with semaglutide vs -6.4% with liraglutide (difference, -9.4 percentage points [95% CI, -12.0 to -6.8]; P < .001
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503701
03HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, liraglutide 3.0 mg daily gave a mean weight change of -6.4% against -1.9% with pooled placebo.
In plain wordsIn adults with overweight or obesity, liraglutide gave 6.4% weight loss against 1.9% with placebo over 68 weeks.
Peptide
Liraglutide
Outcome
DecreasePercentage change in body weight at week 68 versus pooled placebo
Study
n = 127
Comparator
Pooled placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg once daily · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Weight change
−6.4%
liraglutide 3.0 mg
Weight change
−1.9%
pooled placebo
Source sentences
Summary
The mean weight change from baseline was -15.8% with semaglutide vs -6.4% with liraglutide (difference, -9.4 percentage points [95% CI, -12.0 to -6.8]; P < .001); weight change with pooled placebo was -1.9%
3 context sentences(design, population, supporting numbers)
Summary · context
Comparisons of active treatments vs pooled placebo were supportive secondary end points.
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503709
04HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, 25.6% reached 10% or more weight loss with liraglutide versus 70.9% with semaglutide.
In plain wordsIn adults with overweight or obesity, 25.6% on liraglutide lost 10% or more of their weight, against 70.9% on semaglutide.
Peptide
Liraglutide
Outcome
DecreaseAchievement of 10% or more weight loss
Study
n = 127
Comparator
Semaglutide 2.4 mg
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg once daily · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Proportion with 10% or more weight loss
25.6%
liraglutide 3.0 mg
Source sentences
Summary
Participants had significantly greater odds of achieving 10% or more, 15% or more, and 20% or more weight loss with semaglutide vs liraglutide (70.9% of participants vs 25.6% [odds ratio, 6.3 {95% CI, 3.5 to 11.2}], 55.6% vs 12.0% [odds ratio, 7.9 {95% CI, 4.1 to 15.4}], and 38.5% vs 6.0% [odds rati…
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503710
05HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, 12.0% reached 15% or more weight loss with liraglutide versus 55.6% with semaglutide.
In plain wordsIn adults with overweight or obesity, 12.0% on liraglutide lost 15% or more of their weight, against 55.6% on semaglutide.
Peptide
Liraglutide
Outcome
DecreaseAchievement of 15% or more weight loss
Study
n = 127
Comparator
Semaglutide 2.4 mg
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg once daily · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Proportion with 15% or more weight loss
12%
liraglutide 3.0 mg
Source sentences
Summary
Participants had significantly greater odds of achieving 10% or more, 15% or more, and 20% or more weight loss with semaglutide vs liraglutide (70.9% of participants vs 25.6% [odds ratio, 6.3 {95% CI, 3.5 to 11.2}], 55.6% vs 12.0% [odds ratio, 7.9 {95% CI, 4.1 to 15.4}], and 38.5% vs 6.0% [odds rati…
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503711
06HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, 6.0% reached 20% or more weight loss with liraglutide versus 38.5% with semaglutide.
In plain wordsIn adults with overweight or obesity, 6.0% on liraglutide lost 20% or more of their weight, against 38.5% on semaglutide.
Peptide
Liraglutide
Outcome
DecreaseAchievement of 20% or more weight loss
Study
n = 127
Comparator
Semaglutide 2.4 mg
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg once daily · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Proportion with 20% or more weight loss
6%
liraglutide 3.0 mg
Source sentences
Summary
Participants had significantly greater odds of achieving 10% or more, 15% or more, and 20% or more weight loss with semaglutide vs liraglutide (70.9% of participants vs 25.6% [odds ratio, 6.3 {95% CI, 3.5 to 11.2}], 55.6% vs 12.0% [odds ratio, 7.9 {95% CI, 4.1 to 15.4}], and 38.5% vs 6.0% [odds rati…
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503712
07HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, semaglutide 2.4 mg reduced body weight by 15.8% versus 1.9% with pooled placebo.
In plain wordsIn adults with overweight or obesity, semaglutide led to more weight loss than placebo after 68 weeks.
Peptide
Semaglutide
Outcome
DecreasePercentage change in body weight, semaglutide vs pooled placebo
Study
n: not reported in source
Comparator
Placebo (pooled)
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Mean weight change
−15.8%
semaglutide
Mean weight change
−1.9%
pooled placebo
Source sentences
Summary
The mean weight change from baseline was -15.8% with semaglutide vs -6.4% with liraglutide (difference, -9.4 percentage points [95% CI, -12.0 to -6.8]; P < .001); weight change with pooled placebo was -1.9%.
3 context sentences(design, population, supporting numbers)
Summary · context
Comparisons of active treatments vs pooled placebo were supportive secondary end points.
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503702
08HumanRandomized controlled trialEfficacy outcome
More adults reached weight loss of 10% or more with semaglutide than with liraglutide (70.9% vs 25.6%).
In plain wordsMore adults lost at least 10% of their weight with semaglutide than with liraglutide.
Peptide
Semaglutide
Outcome
IncreaseWeight loss of 10% or more
Study
n: not reported in source
Comparator
Liraglutide 3.0 mg once daily
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Proportion
70.9%
semaglutide
Proportion
25.6%
liraglutide
Odds ratio
6.3 ratio
semaglutide vs liraglutide
Source sentences
Summary
70.9% of participants vs 25.6% [odds ratio, 6.3 {95% CI, 3.5 to 11.2}]
3 context sentences(design, population, supporting numbers)
Summary · context
Participants had significantly greater odds of achieving 10% or more, 15% or more, and 20% or more weight loss with semaglutide vs liraglutide
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503703
09HumanRandomized controlled trialEfficacy outcome
More adults reached weight loss of 15% or more with semaglutide than with liraglutide (55.6% vs 12.0%).
In plain wordsMore adults lost at least 15% of their weight with semaglutide than with liraglutide.
Peptide
Semaglutide
Outcome
IncreaseWeight loss of 15% or more
Study
n: not reported in source
Comparator
Liraglutide 3.0 mg once daily
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Proportion
55.6%
semaglutide
Proportion
12%
liraglutide
Odds ratio
7.9 ratio
semaglutide vs liraglutide
Source sentences
Summary
55.6% vs 12.0% [odds ratio, 7.9 {95% CI, 4.1 to 15.4}]
3 context sentences(design, population, supporting numbers)
Summary · context
Participants had significantly greater odds of achieving 10% or more, 15% or more, and 20% or more weight loss with semaglutide vs liraglutide
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503704
10HumanRandomized controlled trialEfficacy outcome
More adults reached weight loss of 20% or more with semaglutide than with liraglutide (38.5% vs 6.0%).
In plain wordsMore adults lost at least 20% of their weight with semaglutide than with liraglutide.
Peptide
Semaglutide
Outcome
IncreaseWeight loss of 20% or more
Study
n: not reported in source
Comparator
Liraglutide 3.0 mg once daily
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Proportion
38.5%
semaglutide
Proportion
6%
liraglutide
Odds ratio
8.2 ratio
semaglutide vs liraglutide
Source sentences
Summary
38.5% vs 6.0% [odds ratio, 8.2 {95% CI, 3.5 to 19.1}]
3 context sentences(design, population, supporting numbers)
Summary · context
Participants had significantly greater odds of achieving 10% or more, 15% or more, and 20% or more weight loss with semaglutide vs liraglutide
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503705
11HumanRandomized controlled trialSafety outcome
In adults with overweight or obesity without diabetes, 27.6% discontinued liraglutide for any reason versus 13.5% on semaglutide.
In plain wordsIn adults with overweight or obesity, 27.6% stopped liraglutide for any reason, against 13.5% on semaglutide.
Peptide
Liraglutide
Outcome
IncreaseDiscontinuation of treatment for any reason
Study
n = 127
Comparator
Semaglutide 2.4 mg
Outcome group
Adverse events · Whole body
Studied dose
3.0 mg once daily · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Discontinuation
27.6%
liraglutide 3.0 mg
Source sentences
Summary
Proportions of participants discontinuing treatment for any reason were 13.5% with semaglutide and 27.6% with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503713
12HumanRandomized controlled trialSafety outcome
In adults with overweight or obesity without diabetes, 82.7% reported gastrointestinal adverse events with liraglutide versus 84.1% with semaglutide.
In plain wordsIn adults with overweight or obesity, 82.7% on liraglutide had stomach or gut side effects, against 84.1% on semaglutide.
Peptide
Liraglutide
Outcome
Direction not reportedGastrointestinal adverse events
Study
n = 127
Comparator
Semaglutide 2.4 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
3.0 mg once daily · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Gastrointestinal adverse events
82.7%
liraglutide 3.0 mg
Source sentences
Summary
Gastrointestinal adverse events were reported by 84.1% with semaglutide and 82.7% with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503714
13HumanRandomized controlled trialSafety outcome
Treatment was stopped for any reason by 13.5% of participants with semaglutide and 27.6% with liraglutide.
In plain wordsFewer people stopped treatment with semaglutide (13.5%) than with liraglutide (27.6%).
Peptide
Semaglutide
Outcome
DecreaseDiscontinuation of treatment for any reason
Study
n: not reported in source
Comparator
Liraglutide 3.0 mg once daily
Outcome group
Adverse events · Whole body
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Discontinuation
13.5%
semaglutide
Discontinuation
27.6%
liraglutide
Source sentences
Summary
Proportions of participants discontinuing treatment for any reason were 13.5% with semaglutide and 27.6% with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503706
14HumanRandomized controlled trialSafety outcome
Gastrointestinal adverse events were reported by 84.1% of participants with semaglutide and 82.7% with liraglutide.
In plain wordsStomach and gut side effects were reported by 84.1% of people with semaglutide and 82.7% with liraglutide.
Peptide
Semaglutide
Outcome
Direction not reportedGastrointestinal adverse events
Study
n: not reported in source
Comparator
Liraglutide 3.0 mg once daily
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Gastrointestinal adverse events
84.1%
semaglutide
Gastrointestinal adverse events
82.7%
liraglutide
Source sentences
Summary
Gastrointestinal adverse events were reported by 84.1% with semaglutide and 82.7% with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Summary · context
Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity.
Report a problemFND-3501503707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT06438146

LIROH - Liraglutide for Obesity in HIV

Brigham and Women's Hospitaln = 402 May 2024 to est. May 2025

Obesity · HIV Infections

Trial page ClinicalTrials.govUpdated 31 May 2024

CompletedPhase 4NCT05574439

Young Adults With Early-onset Obesity Treated With Semaglutide

Signe Torekovn = 24630 May 2022 to 1 Apr 2026

Obesity, Adolescent

Trial page ClinicalTrials.govUpdated 8 Jul 2026

CompletedPhase 3Results postedNCT04074161

Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

Novo Nordisk A/Sn = 33811 Sept 2019 to 11 May 2021

Overweight · Obesity

Trial page ClinicalTrials.govUpdated 19 May 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.